Fox Run Management, L.L.C. Catalyst Pharmaceuticals, Inc. Transaction History
Fox Run Management, L.L.C.
- $526 Million
- Q4 2024
A detailed history of Fox Run Management, L.L.C. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 37,982 shares of CPRX stock, worth $976,897. This represents 0.15% of its overall portfolio holdings.
Number of Shares
37,982
Previous 45,650
16.8%
Holding current value
$976,897
Previous $907,000
12.68%
% of portfolio
0.15%
Previous 0.21%
Shares
4 transactions
Others Institutions Holding CPRX
# of Institutions
348Shares Held
98.5MCall Options Held
13.4KPut Options Held
11.7K-
Black Rock Inc. New York, NY18.7MShares$481 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$217 Million0.0% of portfolio
-
State Street Corp Boston, MA5.8MShares$149 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.13MShares$80.6 Million1.62% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.01MShares$77.5 Million0.02% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.64B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...